These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8754189)

  • 21. [Treatment and follow-up of superficial bladder cancer].
    Raitanen M
    Duodecim; 2002; 118(9):903-9. PubMed ID: 12238168
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of high-risk, non-muscle-invasive bladder cancer.
    Lerner SP
    Nat Clin Pract Urol; 2006 Aug; 3(8):398-9. PubMed ID: 16902498
    [No Abstract]   [Full Text] [Related]  

  • 23. The management of superficial transitional cell carcinoma of the bladder: a critical assessment of contemporary concepts and future perspectives.
    Vögeli TA
    BJU Int; 2005 Dec; 96(8):1171-6. PubMed ID: 16285875
    [No Abstract]   [Full Text] [Related]  

  • 24. Advances in diagnosis and therapy of transitional cell carcinoma of the bladder.
    Lerner SP
    Urol Oncol; 2006; 24(4):324-5. PubMed ID: 16818186
    [No Abstract]   [Full Text] [Related]  

  • 25. Muscle-invasive bladder tumour: can the bladder be preserved?
    Sella A
    BJU Int; 2008 Nov; 102(9):1053-4. PubMed ID: 18715247
    [No Abstract]   [Full Text] [Related]  

  • 26. [Therapeutic approach to bladder cancer classified as T3].
    Burette R
    Cancer Radiother; 1998 Apr; 2 Suppl 1():16s. PubMed ID: 9749071
    [No Abstract]   [Full Text] [Related]  

  • 27. Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.
    Brake M; Loertzer H; Horsch R; Keller H
    J Urol; 2000 Jun; 163(6):1697-701. PubMed ID: 10799163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Sequential changes in superficial bladder cancer].
    Matsuda M
    Nihon Hinyokika Gakkai Zasshi; 1989; 80(13 Suppl):1881-2. PubMed ID: 2485846
    [No Abstract]   [Full Text] [Related]  

  • 29. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
    Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
    J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary management of stage T1 transitional cell carcinoma of the bladder.
    Sataa S; Yassine N; Ghassen HH; Imed BS; Mohamed C; Maher C; Ali H
    Tunis Med; 2005 Dec; 83 Suppl 12():87-9. PubMed ID: 16430077
    [No Abstract]   [Full Text] [Related]  

  • 31. Low dose Pasteur bacillus Calmette-Guerin regimen in stage T1, grade 3 bladder cancer therapy.
    Hurle R; Losa A; Ranieri A; Graziotti P; Lembo A
    J Urol; 1996 Nov; 156(5):1602-5. PubMed ID: 8863547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Infiltrating bladder tumors (P2-P3): therapeutic protocol. Prognostic factors. Analysis of our series].
    Chicharro Molero JA; Pinzón Bohorquez J; Quiñonero Díaz A; Padillá León M; Santos García-Vaquero I; Burgos Rodríguez R; López Rueda B; Gutierrez Calzada JL
    Actas Urol Esp; 1988; 12(5):449-55. PubMed ID: 3218584
    [No Abstract]   [Full Text] [Related]  

  • 33. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
    Leibovici D; Zisman A; Lindner A
    Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
    [No Abstract]   [Full Text] [Related]  

  • 34. [Prognosis in pT3b infiltrating tumors of the bladder treated by adjuvant chemotherapy].
    Sahwi A; Robert M; Delbos O; Legouffe E; Guiter J; Navratil H
    Prog Urol; 1998 Dec; 8(6):1007-11. PubMed ID: 9894259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bladder cancer: clinical practice.
    Rabinowits G; Laber DA
    J Ky Med Assoc; 2009 Apr; 107(4):129-33. PubMed ID: 19419018
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association of statin use with improved local control in patients treated with selective bladder preservation for muscle-invasive bladder cancer.
    Tsai HK; Katz MS; Coen JJ; Zietman AL; Kaufman DS; Shipley WU
    Urology; 2006 Dec; 68(6):1188-92. PubMed ID: 17141846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinicopathological study of 218 patients with bladder carcinoma treated by radical cystectomy].
    Mitsuhata N; Takenaka T; Uesugi T; Mannami R; Mannami M; Shishido S; Masuda H; Nakano Y
    Gan To Kagaku Ryoho; 1997 Dec; 24(15):2239-44. PubMed ID: 9422068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymphovascular invasion as an independent predictor of recurrence and survival in node-negative bladder cancer remains to be proven.
    Reuter VE
    J Clin Oncol; 2005 Sep; 23(27):6450-1. PubMed ID: 16129842
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.